Comparison · NCT03505788-e231b6dd
Acetazolamide vs Placebo: Hospital Readmission
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Acetazolamide vs Placebo: Hospital Readmission. Trial comparisons, record NCT03505788-e231b6dd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03505788-e231b6dd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.184 | 0.141 | 0.236 | wilson | |
| Risk in group 2 | 0.174 | 0.132 | 0.225 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00985 | -0.0565 | 0.0762 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.73 | 1.53 | log | |
| Odds ratio, group 1 over group 2 | 1.07 | 0.681 | 1.68 | log | |
| Number needed to treat, for one more participant with the outcome on Acetazolamide than on Placebo | 102 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Acetazolamide | In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide | 47 | 256 | OG001 |
| Group 2 | Placebo | In the placebo group, the patient will receive the standard of care loop diuretics and the placebo | 45 | 259 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Hospital Readmission
- Description
- If a patient is readmitted to the hospital within 3 months, this data will be collected
- Time frame
- 3 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)
- NCT number
- NCT03505788
- Phases
- PHASE4
- Conditions
- Acute Decompensated Heart Failure, Volume Overload
- Interventions
- Acetazolamide, Placebo
- Lead sponsor
- Ziekenhuis Oost-Limburg
- Results first posted
- 2024-10-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03505788?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03505788-e231b6dd